ClinicalTrials.gg
RecruitingNCT07173530Updated Sep 15, 2025

Low Level Light Therapy & Skin Pigmentation

An interventional study of Three 15-minute low-level light therapy sessions using Light Emitting Diodes of wavelength 633nm (Essilor epi-c plus). in Dry Eye and Meibomian Gland Dysfunction (Disorder), sponsored by University of Houston. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by University of Houston · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Planned enrollment
309th of 473
40 · median 60
Started
2025
with 22 others
No phase
136 of 544
10 open now
Primary completion
2026-08
later than 14 of 62 live
Registered
492nd of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 309th largest by planned enrollment of the 473 interventional ones that give a count, is one of 23 that started in 2025, is one of 136 with no phase, reaches primary completion later than 14 of the 62 other live ones, and was the 492nd registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine if there is a difference in eyelid temperature after low-level light therapy (LLLT) in individuals with different amounts of skin pigmentation and dry eye/meibomian gland disease. Participants will have 3 fifteen minute in office LLLT therapy sessions over a period of approximately 7 to 14 days.

Read the detailed description

The primary objective of the study is to determine if there is a difference in the thermal effect of low-level light therapy (LLLT) in individuals with different skin pigmentation (Fitzpatrick skin type I-IV verses Fitzpatrick skin type V-VI) using a clinically available 633nm LLLT system, the Epi-C-Plus (Espansione group, Bologna, Italy).

03

Conditions studied

  • Dry Eye
  • Meibomian Gland Dysfunction (Disorder)

Keywords

  • Dry Eye
  • Meibomian Gland
  • LLLT
  • Low-level light therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to read and understand the study in English
  • Age 18 years or older at enrollment
  • Individuals with MGD based on one or more of the following clinical signs/symptoms, e.g., meibum quality score of 1-3 (Bron et al.), meibography score of 1, 2, or 3 on the Pult Meiboscale, non-invasive 1st tear break up time of 10 seconds or less, or an Ocular Surface Disease Index (OSDI) score greater than 12 points.

Exclusion criteria

Exclusion Criteria:

  • Active anterior segment pathology (e.g., bacterial conjunctivitis, microbial keratitis)
  • History of systemic disease associated with aqueous-deficient dry eye disease (e.g., Sjogren's syndrome)
  • History of corneal surgery, refractive surgery, or eyelid surgery within 6 months
  • History of corneal ectasia (e.g. keratoconus, Pellucid marginal degeneration)
  • History of ocular trauma within 6 months
  • History of LipiFlow, iLux, Meiboflow, IPL or LLLT within the last 12 months
  • Habitual use of photosensitizing medications within the last 30 days
  • Pregnant and/or lactating females, by self-report
  • Pigmented lesions, tattoos, or skin cancer in the periocular region
  • Unwilling to have eyes photographed or video recorded
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Fitzpatrick skin tone I-IV

    Individuals with skin tones I-IV on the Fitzpatrick scale will receive low-level light therapy

    Device: Three 15-minute low-level light therapy sessions using Light Emitting Diodes of wavelength 633nm (Essilor epi-c plus).

  • Experimental
    Fitzpatrick skin tone V-VI

    Individuals with skin tones V-Vi on the Fitzpatrick scale will receive low-level light therapy

    Device: Three 15-minute low-level light therapy sessions using Light Emitting Diodes of wavelength 633nm (Essilor epi-c plus).

Interventions

  • DeviceThree 15-minute low-level light therapy sessions using Light Emitting Diodes of wavelength 633nm (Essilor epi-c plus).

    A mask with Light Emitting Diodes wavelength 633nm will be placed over closed eyes for 15 minutes.

06

What researchers measure

Primary outcomes

  1. Eyelid temperature

    Time frame: Eyelid temperature will be measured before and after 15 minutes of low-level light therapy at the baseline visit.

Secondary outcomes

  1. Ocular Surface Disease Index Questionnaire

    Time frame: After 3 low-level light therapy treatment sessions through study completion, an average of 1 week.

  2. Tear break up time

    Time frame: After 3 low-level light therapy treatment sessions through study completion, an average of 1 week.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Aug 2026, 14 months after the start.

Of 200 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's planned 14 months is above that.

Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Sep 15, 2025
StartActual
Jun 11, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07173530
Responsible party
Eric R. Ritchey (Associate Professor, University of Houston) — Principal investigator
First posted
Sep 15, 2025
Start date
Jun 11, 2025
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Sep 15, 2025

Study contacts

Eric Ritchey, OD, PhD
Contact
erritche@central.uh.edu
713-743-1933
Rachel Redfern, OD, PhD
Contact
rredfern@uh.edu
713-743-1943

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion